TY - JOUR
T1 - Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3
AU - Pillai, Vinodkumar B.
AU - Samant, Sadhana
AU - Sundaresan, Nagalingam R.
AU - Raghuraman, Hariharasundaram
AU - Kim, Gene
AU - Bonner, Michael Y.
AU - Arbiser, Jack L.
AU - Walker, Douglas I.
AU - Jones, Dean P.
AU - Gius, David
AU - Gupta, Mahesh P.
N1 - Funding Information:
This study was supported by the NIH-RO1 grants HL117041 and HL111455 to M.P.G. NIH-RO1 AR47901 and Rabinowitch-Davis foundation and Margolis Foundation grants to J.A and NCI-1RO1CA152601-01, 1RO1CA152799-01A1, 1RO1CA168292-01A1 and a Northwestern Avon Foundation Center of Excellence grant to D.G. We thank Dr F.W. Alt for providing SIRT3-KO mice. We also thank Dr Vytas Bindokas, Dr Christine Labno, Shirley Bond and Yimei Chen for helping in microscopy work.
Publisher Copyright:
© 2015 Macmillan Publishers Limited. All rights reserved.
PY - 2015/4/14
Y1 - 2015/4/14
N2 - Honokiol (HKL) is a natural biphenolic compound derived from the bark of magnolia trees with anti-inflammatory, anti-oxidative, anti-tumour and neuroprotective properties. Here we show that HKL blocks agonist-induced and pressure overload-mediated, cardiac hypertrophic responses, and ameliorates pre-existing cardiac hypertrophy, in mice. Our data suggest that the anti-hypertrophic effects of HKL depend on activation of the deacetylase Sirt3. We demonstrate that HKL is present in mitochondria, enhances Sirt3 expression nearly twofold and suggest that HKL may bind to Sirt3 to further increase its activity. Increased Sirt3 activity is associated with reduced acetylation of mitochondrial Sirt3 substrates, MnSOD and oligomycin-sensitivity conferring protein (OSCP). HKL-treatment increases mitochondrial rate of oxygen consumption and reduces ROS synthesis in wild type, but not in Sirt3-KO cells. Moreover, HKL-treatment blocks cardiac fibroblast proliferation and differentiation to myofibroblasts in a Sirt3-dependent manner. These results suggest that HKL is a pharmacological activator of Sirt3 capable of blocking, and even reversing, the cardiac hypertrophic response.
AB - Honokiol (HKL) is a natural biphenolic compound derived from the bark of magnolia trees with anti-inflammatory, anti-oxidative, anti-tumour and neuroprotective properties. Here we show that HKL blocks agonist-induced and pressure overload-mediated, cardiac hypertrophic responses, and ameliorates pre-existing cardiac hypertrophy, in mice. Our data suggest that the anti-hypertrophic effects of HKL depend on activation of the deacetylase Sirt3. We demonstrate that HKL is present in mitochondria, enhances Sirt3 expression nearly twofold and suggest that HKL may bind to Sirt3 to further increase its activity. Increased Sirt3 activity is associated with reduced acetylation of mitochondrial Sirt3 substrates, MnSOD and oligomycin-sensitivity conferring protein (OSCP). HKL-treatment increases mitochondrial rate of oxygen consumption and reduces ROS synthesis in wild type, but not in Sirt3-KO cells. Moreover, HKL-treatment blocks cardiac fibroblast proliferation and differentiation to myofibroblasts in a Sirt3-dependent manner. These results suggest that HKL is a pharmacological activator of Sirt3 capable of blocking, and even reversing, the cardiac hypertrophic response.
UR - http://www.scopus.com/inward/record.url?scp=84928162648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928162648&partnerID=8YFLogxK
U2 - 10.1038/ncomms7656
DO - 10.1038/ncomms7656
M3 - Article
C2 - 25871545
AN - SCOPUS:84928162648
SN - 2041-1723
VL - 6
JO - Nature Communications
JF - Nature Communications
M1 - 6656
ER -